文献速递乳腺外科

基于人群的MIA与MSKCC工具预测前哨淋巴结状态的验证

Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status.
PubMed 文献 · JAMA Surg · 2024-01-01

本研究利用瑞典黑色素瘤登记处2007年1月至2021年12月连续纳入的10089例接受前哨淋巴结活检的皮肤黑色素瘤患者,评估MSKCC模型与简化MIA模型的预测效能与临床效用。两种模型在全预测概率范围内校准良好,AUC相似(MSKCC 70.8%,95%CI 69.5-72.1;简化MIA 69.7%,95%CI 68.4-71.1)。决策曲线分析显示,风险阈值≥7%时模型较全部患者活检增加净获益,T2黑色素瘤10%阈值下获益最大。

要点

  • MSKCC与简化MIA模型在10089例瑞典皮肤黑色素瘤队列中校准良好,AUC分别为70.8%与69.7%。
  • 风险阈值5%时两种模型较全部患者行前哨淋巴结活检无额外净获益。
  • 风险阈值≥10%时两种模型均增加净获益,T2黑色素瘤10%阈值下MSKCC每100例减少8例可避免活检,简化MIA减少7例。

核心结论

  • 本研究在大型全国代表性数据集中证实了MSKCC与简化MIA模型的统计性能。
  • 决策曲线分析表明,仅当风险阈值至少为7%时,使用模型较全部患者活检才能改善前哨淋巴结活检选择,T2黑色素瘤10%阈值下获益最大。
  • 在最低阈值下使用这些列线图指导前哨淋巴结活检选择时应谨慎。

研究设计与样本

  • 基于人群的比较效果研究,纳入瑞典黑色素瘤登记处2007年1月至2021年12月连续10089例接受前哨淋巴结活检的皮肤黑色素瘤患者。
  • 数据分析时间为2023年5月至2023年8月。
  • 使用MSKCC模型和简化MIA模型(有丝分裂率按 absent/present 而非 count/mm2,并排除可选变量淋巴血管侵犯)计算每位患者前哨淋巴结阳性的预测概率。

主要发现

  • 10089例患者中位(IQR)年龄64.0(52.0-73.0)岁,男性5340例(52.9%)。
  • 中位Breslow厚度1.8 mm,前哨淋巴结阳性1802例(17.9%)。
  • 两种模型在全预测概率范围内校准良好,外部AUC相似:MSKCC 70.8%(95%CI 69.5-72.1),简化MIA 69.7%(95%CI 68.4-71.1)。
  • 风险阈值5%时,决策曲线分析显示两种模型较全部患者行前哨淋巴结活检均无额外净获益;风险阈值≥10%时两种模型均增加净获益。
  • T2黑色素瘤10%阈值下获益最大,MSKCC列线图每100例患者净减少8例可避免的前哨淋巴结活检,简化MIA每100例净减少7例。

关键数值与推荐

  • MSKCC模型外部AUC 70.8%(95%CI 69.5-72.1)。
  • 简化MIA模型外部AUC 69.7%(95%CI 68.4-71.1)。
  • 风险阈值5%时两种模型较全部患者活检无额外净获益;风险阈值≥10%时两种模型均增加净获益。
  • T2黑色素瘤10%阈值下,MSKCC列线图每100例净减少8例可避免的前哨淋巴结活检,简化MIA每100例净减少7例。
  • 决策曲线分析显示,仅当风险阈值至少为7%时,使用模型较全部患者活检才能改善前哨淋巴结活检选择。

临床怎么用

  • 原文结论未据此给出具体临床推荐,仅指出在最低阈值下使用这些列线图指导前哨淋巴结活检选择时应谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with melanoma are selected for sentinel lymph node biopsy (SLNB) based on their risk of a positive SLN. To improve selection, the Memorial Sloan Kettering Cancer Center (MSKCC) and Melanoma Institute Australia (MIA) developed predictive models, but the utility of these models remains to be tested. OBJECTIVE: To determine the clinical utility of the MIA and MSKCC models. DESIGN, SETTING, AND PARTICIPANTS: This was a population-based comparative effectiveness research study including 10 089 consecutive patients with cutaneous melanoma undergoing SLNB from the Swedish Melanoma Registry from January 2007 to December 2021. Data were analyzed from May to August 2023. MAIN OUTCOMES AND MEASURES,: The predicted probability of SLN positivity was calculated using the MSKCC model and a limited MIA model (using mitotic rate as absent/present instead of count/mm2 and excluding the optional variable lymphovascular invasion) for each patient. The operating characteristics of the models were assessed and compared. The clinical utility of each model was assessed using decision curve analysis and compared with a strategy of performing SLNB on all patients. RESULTS: Among 10 089 included patients, the median (IQR) age was 64.0 (52.0-73.0) years, and 5340 (52.9%) were male. The median Breslow thickness was 1.8 mm, and 1802 patients (17.9%) had a positive SLN. Both models were well calibrated across the full range of predicted probabilities and had similar external area under the receiver operating characteristic curves (AUC; MSKCC: 70.8%; 95% CI, 69.5-72.1 and limited MIA: 69.7%; 95% CI, 68.4-71.1). At a risk threshold of 5%, decision curve analysis indicated no added net benefit for either model compared to performing SLNB for all patients. At risk thresholds of 10% or higher, both models added net benefit compared to SLNB for all patients. The greatest benefit was observed in patients with T2 melanomas using a threshold of 10%; in that setting, the use of the nomograms led to a net reduction of 8 avoidable SLNBs per 100 patients for the MSKCC nomogram and 7 per 100 patients for the limited MIA nomogram compared to a strategy of SLNB for all. CONCLUSIONS AND RELEVANCE: This study confirmed the statistical performance of both the MSKCC and limited MIA models in a large, nationally representative data set. However, decision curve analysis demonstrated that using the models only improved selection for SLNB compared to biopsy in all patients when a risk threshold of at least 7% was used, with the greatest benefit seen for T2 melanomas at a threshold of 10%. Care should be taken when using these nomograms to guide selection for SLNB at the lowest thresholds.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Olofsson Bagge R, Mikiver R, Marchetti MA, et al. Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. JAMA Surg. 2024. PMID: 38198163. doi:10.1001/jamasurg.2023.6904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。